RxSight (RXST) Projected to Post Earnings on Wednesday

RxSight (NASDAQ:RXST - Get Free Report) is projected to issue its quarterly earnings data after the market closes on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $38.74 million for the quarter.

RxSight (NASDAQ:RXST - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.25). The company had revenue of $40.21 million during the quarter, compared to the consensus estimate of $40.23 million. RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. On average, analysts expect RxSight to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

RxSight Trading Down 4.5 %

RxSight stock traded down $0.71 during trading hours on Monday, hitting $15.14. 143,646 shares of the stock traded hands, compared to its average volume of 646,320. The company has a market cap of $615.03 million, a PE ratio of -18.33 and a beta of 1.26. The firm's 50-day moving average price is $20.67 and its two-hundred day moving average price is $32.52. RxSight has a one year low of $13.50 and a one year high of $66.54.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. UBS Group lowered shares of RxSight from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $45.00 to $16.00 in a research note on Wednesday, April 9th. Bank of America restated an "underperform" rating and set a $22.00 price target (down from $36.00) on shares of RxSight in a report on Thursday, April 3rd. Needham & Company LLC reaffirmed a "buy" rating and issued a $43.00 price target on shares of RxSight in a research report on Thursday, April 3rd. Piper Sandler started coverage on shares of RxSight in a research note on Tuesday, April 15th. They set a "neutral" rating and a $18.00 price objective for the company. Finally, JPMorgan Chase & Co. reiterated an "underweight" rating and issued a $17.00 target price (down previously from $40.00) on shares of RxSight in a research note on Friday, April 4th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $37.60.

Insider Activity at RxSight

In other RxSight news, Director Tamara Fountain sold 7,000 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total transaction of $179,970.00. Following the completion of the sale, the director now directly owns 24,793 shares in the company, valued at $637,428.03. The trade was a 22.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 9.36% of the stock is owned by insiders.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.